Development of Superficial Thrombophlebitis and Subsequent Central Retinal Vein Occlusion Occurring in a Patient Receiving IVIg for Ocular Pemphigoid
IVIg can effectively control severe oMMP but may increase the risk of thromboembolic events in predisposed individuals. Recurrent STP during IVIg therapy may serve as an early indicator of a more serious vascular complication, such as CRVO. Recognizing and investigating hypercoagulability in these patients is critical for preventing irreversible vision loss and guiding safer therapeutic strategies.
Authors
- Guangxu Tu (ORCID: https://orcid.org/0000-0003-2920-5387)
- Elmer Y. Tu (ORCID: https://orcid.org/0000-0002-3765-2569)
- Kyle T. Amber (ORCID: https://orcid.org/0000-0002-2906-2454)
- M Mihăilescu (ORCID: https://orcid.org/0000-0001-9249-0534)
- Kevin M. Truong-Balderas (ORCID: https://orcid.org/0009-0004-8621-6538)
Institutions
- Rush University Medical Center (US)
- Illinois College (US)
- New York Eye and Ear Infirmary (US)
- University of Illinois Chicago (US)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1080/09273948.2025.2553871
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00